한글목차

농가진 치료제 세계 시장은 2030년까지 21억 달러에 이를 전망

2023년에 15억 달러로 추정되는 농가진 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 4.5%로 성장하여 2030년에는 21억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 푸시단 드래그는 CAGR 5.1%로 성장을 지속하고, 분석 기간 종료 시에는 8억 8,350만 달러에 달할 것으로 예측됩니다. 퀴놀론 계 약물 부문의 성장률은 분석 기간 동안 CAGR 3.2%로 추정됩니다.

미국 시장은 4억 2,210만 달러로 추정, 중국은 CAGR 7.5%로 성장할 것으로 예측

미국의 농가진 치료제 시장은 2023년 4억 2,210만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 7.5%로 성장을 지속하여 2030년에는 4억 3,280만 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.7%와 4.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.7%로 성장할 것으로 예측됩니다.

세계의 농가진 치료제 시장 - 주요 동향과 촉진요인 정리

전염성 농가진은 주로 유아가 앓는 전염성 세균성 피부 감염이지만 나이에 관계없이 발병할 수 있습니다. 이 감염은 황색 포도상 구균이나 화농 렌사 구균에 의해 유발되며 즉시 파열되어 며칠 동안 삼출되어 황갈색 껍질을 형성하는 붉은 누출이 특징입니다. 농가진은 대개 항생제로 치료되며 누구에게 직접 외용하거나 심한 경우에는 복용합니다. 가장 일반적으로 처방되는 외용 항생제로는 뮤피로신과 푸시딘산이 있으며, 보다 광범위한 감염에는 페니실린, 에리트로마이신, 세팔렉신 등의 경구 항생제가 사용됩니다. 치료법의 선택은 감염의 중증도, 환자의 나이, 기초 질환에 따라 다릅니다.

농가진 치료제 개발의 최근 동향은 기존 치료에 대한 박테리아 균주의 효능 향상과 내성 박테리아 감소에 중점을 둡니다. 연구자들은 외용 항생제의 침투성과 효능을 높이기 위한 새로운 제제 및 전달 시스템을 개발하기 위해 노력하고 있습니다. 또한, 심각한 감염과 내성 감염에 대처하기 위해 외용 항생제와 경구 항생제를 모두 사용하는 병용 요법에 대한 관심이 높아지고 있습니다. 분자생물학과 유전체학의 진보로 신규 항생제 표적의 동정도 가능하게 되어, 내성 메커니즘을 극복할 수 있는 신약 후보의 개발로 이어지고 있습니다. 이러한 기술 혁신은 항생제 내성균의 만연이 증가의 길을 따라 효과적인 농가진 관리에 중대한 과제를 붙이고 있기 때문에 매우 중요합니다.

농가진 치료제 시장의 성장은 여러 요인에 의해 견인되고 있습니다. 농가진의 발생률은 특히 온난하고 습도가 높은 기후와 혼잡한 생활 환경의 지역에서 증가하고 있으며 효과적인 치료에 대한 수요가 높아지고 있습니다. 리포좀 제형 및 나노입자 제형과 같은 약물 전달 시스템의 기술적 진보는 약물의 안정성 향상 및 표적 전달을 제공함으로써 대응가능한 시장을 확대하고 있습니다. 항생제 내성 증가는 새로운 항생제와 병용 요법의 개발에 박차를 가하고 있으며, 이들은 농양진 치료의 효능을 유지하는 데 매우 중요합니다. 게다가 농가진의 증상과 조기 치료의 중요성에 대한 보호자나 헬스케어 관계자의 인식이 높아지고 있는 것도 시장 수요를 뒷받침하고 있습니다. 또한 신흥 시장의 의료 인프라 확충과 의료비 증가도 시장 성장에 기여하고 있습니다. 또한 신규 항생제 개발에 대한 규제 당국의 지원과 중요한 의약품의 신속한 승인 과정이 새로운 치료제 시장 진입을 촉진하고 있습니다. 이러한 요인들이 결합되어 농가진 치료제 시장은 역동적이고 빠르게 발전하고 있습니다.

조사 대상 기업 예(전 86건)

• Grupo Ferrer Internacional, SA
• GSK Plc
• Laboratorios Ojer Pharma SL
• LEO Pharma A/S
• Lytix Biopharma AS
• Medimetriks Pharmaceuticals, Inc.
• NovaBay Pharmaceuticals, Inc.
• Novartis AG
• UNION therapeutics A/S
• Vaxcyte;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Impetigo Drugs Market to Reach US$2.1 Billion by 2030

The global market for Impetigo Drugs estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Fusidane Drug, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$883.5 Million by the end of the analysis period. Growth in the Quinolones Drug segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.1 Million While China is Forecast to Grow at 7.5% CAGR

The Impetigo Drugs market in the U.S. is estimated at US$422.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$432.8 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Impetigo Drugs Market - Key Trends and Drivers Summarized

Impetigo is a highly contagious bacterial skin infection that primarily affects infants and young children, though it can occur in individuals of any age. The infection is caused by Staphylococcus aureus or Streptococcus pyogenes and is characterized by red sores that quickly rupture, ooze for a few days, and then form a yellowish-brown crust. Impetigo is typically treated with antibiotics, either topically applied directly to the sores or taken orally in more severe cases. The most commonly prescribed topical antibiotics include mupirocin and fusidic acid, while oral antibiotics such as penicillin, erythromycin, and cephalexin are used for more extensive infections. The choice of treatment depends on the severity of the infection, the patient's age, and any underlying health conditions.

Recent advancements in the development of impetigo drugs have focused on improving the efficacy and reducing the resistance of bacterial strains to existing treatments. Researchers are working on new formulations and delivery systems to enhance the penetration and effectiveness of topical antibiotics. Moreover, there is growing interest in combination therapies that utilize both topical and oral antibiotics to combat severe or resistant infections. Advances in molecular biology and genomics have also enabled the identification of novel antibiotic targets, leading to the development of new drug candidates that can potentially overcome resistance mechanisms. These innovations are critical as the prevalence of antibiotic-resistant bacteria continues to rise, posing significant challenges to effective impetigo management.

The growth in the impetigo drugs market is driven by several factors. The increasing incidence of impetigo, particularly in regions with warm, humid climates and crowded living conditions, has heightened the demand for effective treatments. Technological advancements in drug delivery systems, such as liposomal and nanoparticle formulations, have expanded the addressable market by offering improved drug stability and targeted delivery. The rise in antibiotic resistance has spurred the development of new antibiotics and combination therapies, which are crucial for maintaining the efficacy of impetigo treatments. Additionally, greater awareness of impetigo symptoms and the importance of early treatment among parents and healthcare providers is driving market demand. The expansion of healthcare infrastructure in emerging markets, along with increased healthcare spending, is also contributing to market growth. Furthermore, regulatory support for the development of new antibiotics and expedited approval processes for critical drugs are facilitating the entry of new treatments into the market. Collectively, these factors are fostering a dynamic and rapidly evolving market for impetigo drugs.

Select Competitors (Total 86 Featured) -

• Grupo Ferrer Internacional, S.A.
• GSK Plc
• Laboratorios Ojer Pharma S.L.
• LEO Pharma A/S
• Lytix Biopharma AS
• Medimetriks Pharmaceuticals, Inc.
• NovaBay Pharmaceuticals, Inc.
• Novartis AG
• UNION therapeutics A/S
• Vaxcyte;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Impetigo Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Impetigo Spurs Demand for Effective Treatments
  • Technological Advancements in Drug Delivery Propel Growth
  • Development of Novel Antibiotics Expands Addressable Market Opportunity
  • Increasing Antibiotic Resistance Strengthens Business Case for New Treatments
  • Here's How Combination Therapies Generate New Market Opportunities
  • Advances in Molecular Biology and Genomics Propel Innovation in Drug Development
  • Growing Healthcare Spending in Emerging Markets Sustains Growth
  • Increasing Number of Clinical Trials Validating Efficacy and Safety of New Drugs Drive Market Confidence
  • Economic Burden of Skin Infections Strengthens Business Case for Effective Solutions
  • Here's the Story: Impact of Pediatric and Geriatric Populations on Market Demand
  • Rising Adoption of Topical Antibiotics Drives Market Growth
  • Expansion of Online Pharmacies Expands Access to Impetigo Drugs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Impetigo Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Fusidane Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Quinolones Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Sulfonamide Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Tetracycline Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 23: Canada Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Canada Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Canada 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• JAPAN
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Japan 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• CHINA
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 29: China Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: China Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: China 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• EUROPE
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• FRANCE
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: France Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: France 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• GERMANY
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 41: Germany Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Germany Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Germany 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Italy Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Italy 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 47: UK Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: UK Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: UK 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 50: Spain Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Spain Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Spain 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 53: Russia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Russia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Russia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Rest of Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 60: Asia-Pacific Historic Review for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 65: Australia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Australia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Australia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• INDIA
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 68: India Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: India Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: India 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 71: South Korea Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: South Korea Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: South Korea 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Rest of Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 77: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 78: Latin America Historic Review for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Latin America 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 80: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 83: Argentina Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Argentina Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Argentina 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 86: Brazil Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Brazil Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Brazil 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 89: Mexico Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Mexico Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Mexico 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 95: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 96: Middle East Historic Review for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Middle East 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 98: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 101: Iran Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Iran Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Iran 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 104: Israel Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Israel Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Israel 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Saudi Arabia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Saudi Arabia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 110: UAE Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UAE Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: UAE 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Rest of Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: Rest of Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
• AFRICA
  • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 116: Africa Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Africa Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: Africa 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION